Q-omics provides the consensus-scored CORO2A profile across patient tissues and cancer cell-line models. CORO2A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CORO2A is differentially expressed in 17, with the highest sampling consensus in THCA. Additionally, CORO2A protein abundance shows 22,369 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where CORO2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORO2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORO2A survival associations across molecular data types. CORO2A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORO2A RNA expression–survival associations across cancer types. High CORO2A expression shows unfavorable associations in KIRP, HNSC, UVM and PAAD, but favorable associations in ACC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CORO2A RNA expression.
This table summarizes CORO2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CORO2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORO2A shows lower tumor expression in COAD and higher tumor expression in THCA, HNSC, BLCA, BRCA and LUSC. The THCA box plot shows higher CORO2A RNA expression in tumor versus normal tissue (log2 FC = +2.137, t-test p < 0.001).
This table shows molecular features associated with CORO2A in patient tissues and cancer cell lines. In patient samples, CORO2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CORO2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
